LECT2 (leucocyte cell‐derived chemotaxin 2) is a 16‐kDa protein mainly produced by hepatocytes. It was first isolated in PHA‐activated human T‐cell leukaemia SKW‐3 cells and originally identified as a novel… Click to show full abstract
LECT2 (leucocyte cell‐derived chemotaxin 2) is a 16‐kDa protein mainly produced by hepatocytes. It was first isolated in PHA‐activated human T‐cell leukaemia SKW‐3 cells and originally identified as a novel neutrophil chemotactic factor. However, many lines of studies suggested that LECT2 was a pleiotropic protein, it not only functioned as a cytokine to exhibit chemotactic property, but also played multifunctional roles in some physiological conditions and pathological abnormalities, involving liver regeneration, neuronal development, HSC(haematopoietic stem cells) homeostasis, liver injury, liver fibrosis, hepatocellular carcinoma, metabolic disorders, inflammatory arthritides, systemic sepsis and systemic amyloidosis. Among the above studies, it was discovered that LECT2 could be a promising molecular biomarker and therapeutic target. This review summarizes LECT2‐related receptors and pathways, basic and clinical researches, primarily in mice and human, for a better comprehension and management of these diseases in the future.
               
Click one of the above tabs to view related content.